Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Kalvista Pharmaceuticals Inc (KALV)

Kalvista Pharmaceuticals Inc (KALV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 830,471
  • Shares Outstanding, K 50,546
  • Annual Sales, $ 0 K
  • Annual Income, $ -183,440 K
  • EBIT $ -191 M
  • EBITDA $ -190 M
  • 60-Month Beta -0.14
  • Price/Sales 593.01
  • Price/Cash Flow N/A
  • Price/Book 48.74

Options Overview Details

View History
  • Implied Volatility 98.55% (+11.94%)
  • Historical Volatility 72.65%
  • IV Percentile 45%
  • IV Rank 17.58%
  • IV High 296.34% on 10/23/25
  • IV Low 56.35% on 03/12/25
  • Expected Move (DTE 11) 4.62 (27.87%)
  • Put/Call Vol Ratio 0.05
  • Today's Volume 22
  • Volume Avg (30-Day) 1,220
  • Put/Call OI Ratio 2.37
  • Today's Open Interest 31,446
  • Open Int (30-Day) 24,149
  • Expected Range 11.97 to 21.21

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.83
  • Number of Estimates 4
  • High Estimate -0.64
  • Low Estimate -1.08
  • Prior Year -0.92
  • Growth Rate Est. (year over year) +9.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.55 +57.58%
on 11/11/25
16.80 -1.04%
on 12/04/25
+5.85 (+54.22%)
since 11/07/25
3-Month
10.41 +59.70%
on 11/07/25
17.28 -3.79%
on 09/11/25
+0.66 (+4.17%)
since 09/08/25
52-Week
7.30 +127.74%
on 01/13/25
17.28 -3.79%
on 09/11/25
+6.81 (+69.47%)
since 12/06/24

Most Recent Stories

More News
KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results

US launch of EKTERLY® gaining strong momentum with $13.7 million in net product revenue for the third quarter 937 patient start forms received through October, reflecting...

KALV : 16.68 (+1.52%)
KalVista Pharmaceuticals Presents New Data Highlighting Patient Satisfaction with EKTERLY® (sebetralstat) and its Potential in Children Ages 2-11 at the ACAAI 2025 Annual Scientific Meeting

KONFIDENT-S participants who switched to sebetralstat reported being very or extremely satisfied Interim results from KONFIDENT-KID show sebetralstat enables early, effective,...

KALV : 16.68 (+1.52%)
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in a fireside chat at each of the following upcoming investor conferences: Stifel...

KALV : 16.68 (+1.52%)
KalVista Pharmaceuticals to Host Third Quarter Financial Results Conference Call and Webcast on November 11, 2025

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) will host a conference call and webcast on Tuesday, November 11, 2025, at 8:30 a.m. ET to review the Company’s third quarter financial results and provide...

KALV : 16.68 (+1.52%)
KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting

KalVista Pharmaceuticals , Inc. (Nasdaq: KALV) today announced the acceptance of one abstract for late-breaking oral presentation and three for poster presentation at the American College of Allergy,...

KALV : 16.68 (+1.52%)
KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting

KalVista Pharmaceuticals , Inc. (Nasdaq: KALV) today announced the acceptance of one abstract for late-breaking oral presentation and three for poster presentation at the American College of Allergy,...

KALV : 16.68 (+1.52%)
KalVista Pharmaceuticals Announces New Executive Appointments

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest...

KALV : 16.68 (+1.52%)
KalVista Pharmaceuticals Presents New Data Highlighting the Potential of EKTERLY® (sebetralstat) to Transform On-Demand Hereditary Angioedema Treatment in Europe

Findings from KONFIDENT and KONFIDENT-S show rapid, effective treatment of HAE attacks among European participants; patient survey highlights barriers linked to injectable therapies

KALV : 16.68 (+1.52%)
KalVista Pharmaceuticals Appoints Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the appointments of Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer, effective October 6, 2025. “I...

KALV : 16.68 (+1.52%)
KalVista Pharmaceuticals Appoints Bethany Sensenig to Board

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. KalVista...

KALV : 16.68 (+1.52%)

Business Summary

KalVista Pharmaceuticals, Inc. is a pharmaceuticals company. It engages in discovery, development and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product portfolio consist hereditary angioedema and diabetic macular edema, KVD818 and KVD001, which...

See More

Key Turning Points

3rd Resistance Point 17.76
2nd Resistance Point 17.23
1st Resistance Point 16.83
Last Price 16.68
1st Support Level 15.90
2nd Support Level 15.37
3rd Support Level 14.97

See More

52-Week High 17.28
Last Price 16.68
Fibonacci 61.8% 13.47
Fibonacci 50% 12.29
Fibonacci 38.2% 11.11
52-Week Low 7.30

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar